论文部分内容阅读
271例Ⅱ型糖尿病患者经用糖适平(GL)治疗5或7个月后,空腹及餐后血糖、HbA_1、尿糖及尿蛋白均较治疗前明显降低(P<0.01).空腹及餐后血糖分别较治前平均降低21.48％和25.41％。GL治疗总有效率为85.6％。低血糖反应发生率为0.7％。其他副反应有嗜睡6例,瘙痒、腹胀和面部刺痛各1例。血像及肝肾功能无特殊变化。本药适应证除与一般磺脲类(SU)相同外,尤适于:(1)老年糖尿病;(2)糖尿病伴轻至中度肾功能减退;(3)用其他SU反复有低血糖发作者;(4)其他SU失效者。GL剂量为112.40±66.50mg/d(15～270mg/d),较国外报告为高。
Fasting and postprandial blood glucose, HbA_1, urine glucose and urine protein in 271 type Ⅱ diabetic patients were significantly lower than those before treatment after 5 or 7 months of treatment with GL (P <0.01) Postprandial blood glucose decreased by an average of 21.48% and 25.41% respectively. The total effective rate of GL treatment was 85.6%. The incidence of hypoglycemia was 0.7%. Other side effects were drowsiness in 6 cases, itching, bloating and facial tingling in 1 case. Blood and liver and kidney function no special changes. This drug indications in addition to the general and the same general sulfonylurea (SU), especially suitable for: (1) senile diabetes; (2) diabetes with mild to moderate renal dysfunction; (3) repeatedly with other SU hypoglycemia Author; (4) Other SU failure. GL dose of 112.40 ± 66.50mg / d (15 ~ 270mg / d), higher than the foreign reports.